Trial Profile
Response to neoadjuvant crizotinib in patients with locally advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2018 New trial record
- 05 Nov 2018 Results published in the Journal of Thoracic Oncology